"The growth hormone/IGF-1 axis is an attractive target for preserving muscle mass in cirrhosis, but the liver's dual role as both a GH effector organ and a metabolic clearance site means that any GH-axis intervention must account for the degree of hepatocellular dysfunction," according to the Endocrine Society's position statement on GH in chronic illness (Endocrine Society Clinical Practice Guideline, 2011)
Animal studies have documented significant improvements in Morris water maze performance, radial arm maze accuracy, and novel object recognition tasks, with effects persisting for extended periods after treatment suggesting lasting changes in neural connectivity rather than temporary pharmacological stimulation
R core team
These drips can complement GLP-1 therapy by improving energy levels, supporting recovery, and helping patients maintain consistent progress
Dao K, Shechtman S, Weber-Schoendorfer C, Diav-Citrin O, Murad RH, Berlin M, et al